Kiniksa Pharmaceuticals/KNSA

$20.19

-7.12%
-
1D1W1MYTD1YMAX

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).

Ticker

KNSA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sanjiv Patel

Employees

297

Headquarters

Hamilton, Bermuda

KNSA Metrics

BasicAdvanced
$1.54B
Market cap
135.93
P/E ratio
$0.16
EPS
0.28
Beta
-
Dividend rate

What the Analysts think about KNSA

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
39.92% upside
High $32.00
Low $25.00
$20.19
Current price
$28.25
Average price target

KNSA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
30.25% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$83.3M
24.33%
Net income
$25.2M
-282.61%
Profit margin
30.25%
-246.92%

KNSA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 350%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.18
$0.21
-$0.20
$0.35
-
Expected
-$0.21
-$0.17
-$0.17
-$0.14
-$0.18
Surprise
-13.25%
-225.37%
19.4%
-350%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Kiniksa Pharmaceuticals stock

Buy or sell Kiniksa Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing